Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm,Multi-center,Phase Ib/II Clinical Study Evaluating IBI310 Combined With Sintilimab in Patients With Advanced Biliary Tract Cance(BTC)

NCT05653180 is registered in ClinicalTrials.gov with Innovent Biologics (Suzhou) Co. Ltd. as lead sponsor.

NCT NCT05653180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05653180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm,Multi-center,Phase Ib/II Clinical Study Evaluating IBI310 Combined With Sintilimab in Patients With Advanced Biliary Tract Cance(BTC)
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 10, 2023
Completion date
June 1, 2024
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced biliary tract cancer